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OBJECTIVE—Insulitis is an important pathological feature of
autoimmune diabetes; however, mechanisms governing the re-
cruitment of diabetogenic T-cells into pancreatic islets are poorly
understood. Here, we determined the importance of leukocyte
integrins 2 (Itgb2) and L (ItgaL) in developing insulitis and
frank diabetes.
RESEARCH DESIGN AND METHODS—Gene-targeted muta-
tions of either Itgb2 or ItgaL were established on the NOD/LtJ
mouse strain. Experiments were performed to measure insulitis
and diabetes development. Studies were also performed measur-
ing mutant T-cell adhesion to islet microvascular endothelial
cells under hydrodynamic ﬂow conditions. T-cell adhesion mol-
ecule proﬁles and adoptive transfer studies were also performed.
RESULTS—Genetic deﬁciency of either Itgb2 or ItgaL com-
pletely prevented the development of hyperglycemia and frank
diabetes in NOD mice. Loss of Itgb2 or ItgaL prevented insulitis
with Itgb2 deﬁciency conferring complete protection. In vitro
hydrodynamic ﬂow adhesion studies also showed that loss of
Itgb2 completely abrogated T-cell adhesion. However, ItgaL
deﬁciency did not alter NOD T-cell adhesion to or transmigration
across islet endothelial cells. Adoptive transfer of ItgaL-deﬁcient
splenocytes into NOD/Rag-1 mice did not result in development
of diabetes, suggesting a role for ItgaL in NOD/LtJ T-cell
activation.
CONCLUSIONS—Together, these data demonstrate that ge-
netic deﬁciency of Itgb2 or ItgaL confers protection against
autoimmune diabetes through distinctly different mechanisms.
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A
utoimmune diabetes results from insulitis, the
inﬁltration of T-cells into the pancreatic islets,
leading to signiﬁcant -cell death. This insti-
gates dysregulation of blood glucose levels,
which has both genetic and environmental causes. The
impetus for T-cell accumulation within pancreatic islets
has been debated; however, activation of autoreactive
CD4
 Th1 (type 1 T-helper) cells (1,2), defective regula-
tory T-cell activity (3), local production of chemokines
(4,5), and increased adhesion molecule expression are
prime culprits (6–9). Although many different types of
leukocytes are involved in insulitis, i.e. CD4
 and CD8
,
T-cells are essential in the pathogenesis of diabetes and
islet damage. Moreover, the speciﬁc molecules and path-
ways regulating T-cell recruitment into pancreatic islets
remain largely unknown.
Regulation of T-cell recruitment is controlled by a host
of cellular events within the microcirculation involving
rolling, cellular activation, ﬁrm adhesion, and subsequent
transmigration across endothelial cell monolayers. Several
different adhesion molecules expressed by both T-cells
and endothelial cells regulate these interactions with
selectin proteins primarily governing rolling and integrin
proteins regulating ﬁrm adhesion and transmigration
(10,11). The multiple overlapping nature of these mole-
cules helps to enable immune responses; however, certain
adhesion molecules may play a more dominant role in the
process, thereby controlling immune cell recruitment.
Two classes of integrins, 1 (Itgb1) and 2 (Itgb2), have
been identiﬁed in regulating T-cell adhesion and homing to
various organs and may be important for homing of
diabetogenic T-cells (12–15). Importantly, both clinical
and animal studies demonstrate that several members of
these integrin protein families are upregulated or differen-
tially engaged during autoimmune diabetes (16–19). How-
ever, no speciﬁc information exists regarding which of the
integrin proteins are critically necessary for development
of autoimmune diabetes or the mechanism by which this
occurs.
The Itgb2 protein family is exclusively expressed on
leukocytes and forms heterodimeric molecules consisting
of a common Itgb2 chain paired with a speciﬁc  chain of
either L (ItgaL), M (ItgaM), X (ItgaX), or D (ItgaD).
We previously reported that the Itgb2 chain is important
for the development of murine autoimmune lupus and
streptozotocin-induced diabetes (12,13). However, the im-
portance of various heterodimer  chains and the molec-
ular disease mechanisms involving Itgb2 proteins during
the development of autoimmune diabetes is not known.
Therefore, we generated NOD/LtJ mice containing gene-
targeted null deletions of Itgb2 or ItgaL to determine
whether these molecules play a role in the development of
spontaneous autoimmune diabetes. Here, we report that
genetic deﬁciency of either Itgb2 or ItgaL confers protec-
tion against the development of frank diabetes and insuli-
tis in NOD mice. However, the protective mechanisms
resulting from the loss of these proteins are distinctly
different from one another. These ﬁndings also demon-
strate that leukocyte Itgb2 predominate over other adhe-
sion molecules during the development of diabetes, and
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RESEARCH DESIGN AND METHODS
Mice used in this study were bred and housed at the Louisiana State University
Health Sciences Center Shreveport animal resource facility, an Association for
Assessment and Accreditation of Laboratory Animal Care International–
accredited facility, and maintained according to the National Research
Council’s Guide for Care and Use of Laboratory Animals. All experiments
reported in this study were approved by our institutional care and use
committee. Gene-targeted null mutations of either Itgb2 or ItgaL were
backcrossed onto the NOD/LtJ strain for at least nine generations. Map pair
microsatellite marker analysis was performed for Idd loci analysis in mutant
and littermate control mice. All known Idd loci were present in all of the
different strains of mice. Results from littermate control wild-type alleles for
either mutation were similar to NOD/LtJ mice; therefore, controls are referred
to as NOD/LtJ throughout the study. Mice were maintained on acidiﬁed water,
sterile caging and bedding, and sterile chow (diet 7012; Harlan Teklad,
Madison, WI). The glucose levels of female wild-type control, Itgb2
/, and
ItgaL
/ NOD/LtJ mice were followed starting at 12 weeks of age. Blood
glucose measurements were taken every week using Ascensia Elite blood
glucose test strips and a Bayer Glucometer Elite until either there were two
consecutive hyperglycemic (250 mg/dl) measurements or the mice reached
34 weeks of age.
Cell culture. Pancreatic islet microvascular endothelial cells were cultured
as we have previously reported (20,21). Cells were grown in high-glucose
DMEM obtained from VWR, supplemented with L-glutamine-penicillin-strep-
tomycin (Sigma) and 5% fetal bovine serum (Atlanta Biologicals). Endothelial
cells cultured in T-75 ﬂasks were seeded into either 35-mm culture dishes (for
use with the parallel plate ﬂow chamber) or Fluoroblock inserts (for the
transmigration assay).
Histology. Pancreata were harvested from wild-type control, Itgb2
/ null
NOD/LtJ, and ItgaL
/ null NOD/LtJ mice as follows. The pancreas was
removed, placed into cassettes, and ﬁxed in 10% buffered neutral formalin.
Specimens were embedded in parafﬁn, sectioned, and stained with hematox-
ylin and eosin. Slides were scored by a blinded observer on a scale of 0 to 4,
with 0 representing no insulitis, 1 peri-insulitis, 2 25% of islet area being
leukocytes, 3 25% of islet area being leukocytes, and 4 being pseudoatrophic
islets without -cells (22). Insulitis scores were generated by evaluating four
serial sections of pancreata per animal. A minimum of 20 islets were scored
per animal to obtain an aggregate insulitis score, which was then combined
with other aggregate scores to obtain the overall insulitis score per genotype.
T-cell isolation. Spleens from different NOD/LtJ mice were removed and
ground between two frosted slides over a petri dish containing buffer (PBS
with 2% fetal bovine serum). Splenocytes were then twice-ﬁltered through a
70-m pore size cell strainer and red cells lysed with 5 ml ACK lysis buffer
(0.15 mmol/l ammonium chloride, 1.0 mmol/l potassium bicarbonate, and 0.1
mmol/l sodium EDTA, pH 7.2) per spleen. The resulting splenocyte population
was then resuspended in buffer at a concentration of 5  10
7 cells/ml. Speciﬁc
T-cell populations were isolated from mouse spleens as we have previously
reported, using a SpinSep mouse T-cell enrichment kit from Stem Cell
Technologies (20).
Flow cytometry. Splenocytes from different NOD/LtJ mice were prepared as
described above and diluted to 1  10
7 cells/ml of buffer. Cells were blocked
with an equal volume of Fc block (anti-mouse CD16/32) and rocked on ice for
15 min. Cells were then either dual- or triple-stained. Cells for two-color ﬂow
cytometry were stained with antibodies against CD3 and one of the following
integrins: ItgaL (CD11a), Itgb2 (CD18), Itgb1 (CD29), Itga4 (CD49d), ItgaM
(CD11b), ItgaX (CD11c), or lymphocyte Peyer’s patch adhesion molecule
(LPAM-1; Itga4/Itgb7). Cells for three-color ﬂow cytometry were stained with
CD3, CD4, and CD8. Specimens were gated on CD3 staining and subsequently
analyzed for CD4/CD8 positivity. Samples were analyzed with a FACS Calibur
ﬂow cytometer (Becton Dickinson) using Cell Quest software (Becton Dick-
inson) by the Research Core Facility at the Louisiana State University Health
Sciences Center. Cells were gated using forward versus side scatter, with
10,000 events collected. All cell staining analyses were performed in triplicate.
Parallel plate ﬂow chamber. CD3 T-cells were prepared for the parallel
plate ﬂow chamber by resuspending the cells in Hanks’ balanced salt solution
(HBSS) as we have previously reported (21). Cells were labeled with Cell-
Tracker Green at a concentration of 6.25 g/ml for 45 min on ice. Cells were
rinsed twice and resuspended at a concentration of 2  10
5 cells/ml of HBSS
and placed in a beaker kept at 37°C and stirred at 60 r/min. A ﬂow chamber
insert and gasket (Glycotech) were used with Corning 35-mm cell culture
dishes to form a parallel plate ﬂow chamber. Cells were pulled across either
unstimulated or tumor necrosis factor- (TNF-)-stimulated (10 ng/ml) islet
microvascular endothelial monolayers in the cell culture dish at a physiolog-
ical shear stress of 1.5 dyn/cm
2. A Nikon Eclipse TE-2000 epiﬂuorescence
microscope and Hamamatsu Digital Camera were used to acquire real-time
digital video of the cells as they were ﬂowed over islet endothelium. We used
Simple PCI software (Compix) to analyze the video and extract rolling
velocities of the T-cells. Cells were considered to be ﬁrmly adherent if they
remained stationary for 10 s within the ﬁeld of view.
T-cell transmigration assays. Pancreatic islet endothelial cells were grown
to conﬂuence on Falcon Fluoroblok tissue culture inserts (8-m pore size; BD,
Franklin Lakes, NJ). T-cells were harvested and labeled as described above.
Labeled CD3
 T-cells at 5  10
5 cells per insert in 750 l HBSS were added to
the luminal compartment of inserts in triplicate, and regulated upon activa-
tion, normal T-cell expressed and secreted (RANTES; 100 ng/ml) or control
HBSS was placed into the abluminal compartment. In some experiments,
TNF- stimulation (10 ng/ml) was used to activate endothelial monolayers
before performing transmigration studies. Plates were incubated at 37°C in a
5% CO2 atmosphere, and ﬂuorescence measurements were taken at 0, 15, 30,
60, and 120 min using a Tecan GENios Plus plate reader. Wells with 0 and
50,000 cells in the abluminal compartment served to provide control settings
for the software.
Diabetes adoptive transfer. Whole splenocytes were isolated from diabetic
NOD/LtJ wild-type or NOD/LtJ ItgaL null mice and injected retro-orbitally (2 
10
7 per mouse) into 8-week-old NOD Rag-1 mutant mice. Blood glucose was
measured weekly until either two consecutive glucose measurements in
excess of 250 mg/dl occurred or until 9 weeks posttransfer, whichever came
ﬁrst. At that point, pancreata were removed, formalin-ﬁxed, and processed
from histological analysis of insulitis. Splenocytes were also obtained; triple-
stained for CD3, CD4, and CD8; and analyzed by ﬂow cytometry.
Statistical analysis. Changes in blood glucose, diabetes incidence, and
insulitis were compared by one-way ANOVA with Bonferroni’s post-test
versus NOD/LtJ controls. Comparison of T-cell biophysical interactions be-
tween unstimulated versus TNF-–stimulated islet endothelial cells was
performed with an unpaired Student’s t test. Changes in T-cell transmigration
across islet endothelial cells was compared against transmigration rates across
unstimulated control islet endothelial monolayers using one-way ANOVA with
Bonferroni’s post-test versus control at each speciﬁed time point. A P value of
0.05 was required for signiﬁcance among all analyses performed with experi-
mental n values reported in the ﬁgure legends.
RESULTS
Lack of Itgb2 or ItgaL is protective against diabetes
and insulitis. Blood glucose data obtained from NOD/LtJ
wild-type, Itgb2
/ null NOD/LtJ, and ItgaL
/ null NOD/
LtJ mice demonstrate that loss of either Itgb2 or ItgaL
offers protection from diabetes. Figure 1A reports that
Itgb2 and ItgaL knockout mice maintained normal blood
glucose levels throughout the study, whereas wild-type
NOD/LtJ mice showed a marked increase between weeks
14 and 16, plateauing at 400 mg/dl by week 24. Only 20% of
NOD/LtJ wild-type mice remained normoglycemic by
week 30, whereas ItgaL
/ and Itgb2
/ mice remained
normoglycemic for the entire study period (Fig. 1B). These
results clearly reveal an important pathophysiological role
for Itgb2 and ItgaL during the onset of diabetes.
Insulitis histopathology of pancreatic islets from age-
matched 18-week-old wild-type, Itgb2
/, and ItgaL
/
NOD/LtJ mice are shown in Fig. 1C–E. Wild-type mice
show a large number of cell inﬁltrates (Fig. 1C), with
Itgb2
/ mice showing no signs of insulitis (Fig. 1D).
ItgaL
/ mouse pancreatic islets also appear essentially
normal; however, some lymphocyte inﬁltrates can be
observed (Fig. 1E). Histopathology sections were scored
for the degree of insulitis (Fig. 1F), with wild-type NOD/LtJ
mice showing a signiﬁcantly higher score than either the
Itgb2
/ or ItgaL
/ mice. Together, these data demon-
strate that Itgb2 or ItgaL expression is necessary for the
development of frank diabetes in the NOD mouse model.
Adhesion molecule expression of NOD/LtJ CD3
T-cells. Figure 2 reports the percent of CD3 T-cells that
express various surface adhesion molecules between wild-
type, Itgb2 null, and ItgaL null NOD/LtJ mice. Adhesion
molecule expression analysis was performed using pre-
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wild-type and mutant mice at 18 weeks of age. As ex-
pected, genetic deﬁciency of Itgb2 eliminates CD18 and
CD11a surface expression (Fig. 2A and B). Interestingly,
genetic deﬁciency of ItgaL does not completely abolish
CD18 surface expression, indicating the presence of other
2 integrins on the T-cell surface (Fig. 2B). This is an
important observation because previous studies have as-
sumed that the only relevant Itgb2 expressed on the T-cell
surface is CD18/CD11a and that genetic deﬁciency of CD18
serves as a surrogate for knockout of CD11a (23,24). Our
data demonstrate that this is clearly not the case and that
genetic disruption of ItgaL still results in a Itgb2 phenotype
in NOD/LtJ mice, highlighting that these molecules are not
interchangeable. Deﬁciency of ItgaL or Itgb2 did not
signiﬁcantly alter CD49d positivity (Fig. 2C); however,
deﬁciency of Itgb2 did signiﬁcantly increase CD29 (1
integrin) positivity (Fig. 2D). Interestingly, genetic deﬁ-
ciency of Itgb2 signiﬁcantly decreased the number of CD3
T-cells positive for CD62L (Fig. 2E), suggesting differential
regulation of adhesion molecule expression between ItgaL
and Itgb2.
Figure 3 reports the mean ﬂuorescence intensity of
adhesion molecule expression on CD3 T-cells from wild-
type and mutant NOD/LtJ mice. Figure 3A shows that
genetic deﬁciency of either ItgaL or Itgb2 signiﬁcantly
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FIG. 1. Genetic deﬁciency of Itgb2 or ItgaL confers protection against autoimmune diabetes in NOD/LtJ mice. A: Blood glucose measurements
from wild-type, Itgb2
/ null, and ItgaL
/ null NOD/LtJ mice over time. B: The percent of mice remaining normoglycemic over time between
wild-type, Itgb2
/ null, and ItgaL
/ null NOD/LtJ mice. C–E: Representative hematoxylin and eosin stains of islet histopathology from wild-type,
Itgb2
/ null, and ItgaL
/ null NOD/LtJ mice, respectively. F: The insulitis score between the different genotypes of NOD/LtJ mice. *P < 0.01 vs.
mutant NOD/LtJ strains, n  20 mice per genotype. ***P < 0.001, n  15 mice per genotype. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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shows that genetic deﬁciency of either molecule also
signiﬁcantly decreases CD18 surface expression. How-
ever, robust CD18 surface expression is observed on ItgaL
CD3 T-cells compared with absent expression on Itgb2
CD3 cells. Again, these data indicate that other 2 integrins
may be expressed in lieu of ItgaL deﬁciency. Interest-
ingly, Itgb2 deﬁciency enhances CD29 surface expres-
sion (Fig. 3D). CD3 T-cell surface expression of CD62L
is similarly decreased in either ItgaL or Itgb2 null mice
(Fig. 3E). Lastly, surface expression of LPAM-1 was
unchanged among wild-type and mutant NOD/LtJ CD3
T-cells (Fig. 3F).
Itgb2 integrin deﬁciency minimally alters NOD/LtJ
T-cell development. Previous studies have shown that
genetic deﬁciency of leukocyte integrins can alter T-cell
development (14,25). Therefore, ﬂow cytometry was per-
formed on ItgaL
/ NOD/LtJ, Itgb2
/ NOD/LtJ, and dia-
betic NOD/LtJ wild-type CD3 T-cells at 18 weeks of age to
determine the effects of these mutations on different T-cell
phenotype populations (Table 1). Wild-type diabetic NOD/
LtJ T-cells show 57% of the T-cells expressing CD4, 36.7%
expressing CD8, and a small double-negative population
(5.3%). Data from ItgaL
/ NOD/LtJ T-cells show essen-
tially the same result. Interestingly, CD3 T-cells from
Itgb2
/ NOD/LtJ mice have a statistically greater number
of double-negative T-cells (21.3%) compared with wild-
type NOD/LtJ mice. Together, these data suggest that
genetic deﬁciency of Itgb2 has a slight impact on NOD/LtJ
double-negative T-cell development, which is not observed
with ItgaL genetic deﬁciency.
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FIG. 2. Genetic deﬁciency of Itgb2 or ItgaL alters the phenotype of NOD/LtJ CD3 T-cells. Whole splenocytes were isolated from wild-type
pre-diabetic (12 weeks old), wild-type diabetic (18 weeks old), Itgb2
/ null (18 weeks old), and ItgaL
/ null (18 weeks old) NOD/LtJ mice and
stained for CD3 and individual adhesion molecules to determine the percentage of cells expressing various molecules. A: The percent of CD3
T-cells that are positive for CD11a expression. B: The percent of CD3 T-cells that are positive for CD18 expression. C: The percent of CD3 T-cells
that are positive for CD49d expression. D: The percent of CD3 T-cells that are positive for CD29 expression. E: The percent of CD3 T-cells that
are positive for CD62L expression. F: The percent of CD3 T-cells that are positive for LPAM-1 expression. *P < 0.01 vs. wild-type diabetic mice;
#P < 0.01 Itgb2 null vs. ItgaL null mice, n  6–7 animals per genotype.
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Insulitis data from Itgb2 null and ItgaL null mice suggest
that these proteins may diminish islet T-cell inﬁltration,
possibly because of defects in cell capture, rolling, or ﬁrm
adhesion. To investigate this possibility, T-cells were iso-
lated from NOD/LtJ wild-type, ItgaL
/, and Itgb2
/ mice
and adhesion dynamics examined using a parallel plate
ﬂow chamber model to emulate physiological leukocyte-
endothelial cell interactions. T-cells from the different
NOD/LtJ mice were ﬂowed over either control- or TNF-
(10 ng/ml)–stimulated pancreatic islet endothelium. TNF-
stimulation upregulates the expression of P-selectin and
E-selectin on islet microvascular endothelial cells, which
are involved in the cell rolling process, as we have
previously reported (20). TNF- stimulation of islet endo-
thelial cells resulted in a signiﬁcant reduction in the
average rolling velocity of NOD/LtJ wild-type, ItgaL
/,
and Itgb2
/ T-cells compared with unstimulated islet
endothelial cells (Fig. 4A). Importantly, there was no
signiﬁcant difference between the average rolling veloci-
ties between any of the cell groups with or without TNF-
stimulation. This demonstrates that genetic deﬁciency of
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FIG. 3. Loss of Itgb2 or ItgaL expression alters NOD/LtJ T-cell adhesion molecule expression. Whole splenocytes were isolated from wild-type
pre-diabetic (12 weeks old), wild-type diabetic (18 weeks old), Itgb2
/ null (18 weeks old), and ItgaL
/ null (18 weeks old) NOD/LtJ mice and
stained for CD3 and individual adhesion molecules to determine the amount of surface adhesion molecule expression. A: The mean ﬂuorescence
intensity for CD11a expression. B: The mean ﬂuorescence intensity for CD18 expression. C: The mean ﬂuorescence intensity for CD49d
expression. D: The mean ﬂuorescence intensity for CD29 expression. E: The mean ﬂuorescence intensity for CD62L expression. F: The mean
ﬂuorescence intensity for LPAM-1 expression. *P < 0.01 vs. wild-type diabetic mice; #P < 0.01 Itgb2 null vs. ItgaL null mice, n  6–7 animals per
genotype.
TABLE 1
Genetic deﬁciency of Itgb2 minimally alters NOD/LtJ T-cell
distribution
Genotype CD4 CD8
Double-
negative
Double-
positive
Wild type 57.0 	 1.8 36.7 	 2.6 5.3 	 0.9 0.56 	 0.07
ItgaL null 60.4 	 3.1 26.4 	 0.8 12.6 	 2.6 0.46 	 0.1
Itgb2 null 50.4 	 3.8 27.6 	 3.2 21.3 	 2.4* 0.31 	 0.03
Data are reported as percent distributions 	SD. Whole splenocytes
were isolated from wild-type diabetic, ItgaL null, or Itgb2 null
NOD/LtJ mice and triple-stained for CD3, CD4, and CD8 to evaluate
T-cell population distributions. *P  0.001 versus wild-type diabetic
NOD/LtJ mice, n 
 5 per genotype.
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tether and roll on islet endothelium.
We have previously reported that treatment of islet
microvascular endothelium with TNF- also increases the
expression of intercellular adhesion molecule-1 and vas-
cular cell adhesion molecule-1 on the islet endothelial
surface, which is crucial for ﬁrm adhesion (20). Figure 4B
shows that NOD/LtJ CD3 T-cell adhesion is signiﬁcantly
increased as expected. In contrast, Itgb2
/ T-cells
showed no statistically signiﬁcant increase in the percent-
age of ﬁrmly adherent cells on stimulated versus unstimu-
lated endothelium. These data suggest that the protection
offered by genetic deﬁciency of Itgb2 is a result of the
inability of the T-cells to ﬁrmly adhere to the endothe-
lium. Surprisingly, T-cells from ItgaL
/ NOD/LtJ mice
still showed an increase in T-cell ﬁrm adhesion on
TNF-–stimulated endothelium along with a slight but
insigniﬁcant increase in ﬁrm adhesion over that of
wild-type NOD/LtJ T-cells. These results demonstrate
that ItgaL expression is not essential for T-cell ﬁrm
adhesion in the NOD/LtJ mouse, suggesting that this
molecule alters the progression of diabetes through
other mechanisms.
Having observed that ItgaL was not necessary for NOD/
LtJ T-cell adhesion, we next evaluated whether ItgaL null
T-cells do not inﬁltrate the pancreatic islets because of a
defect in their ability to transmigrate (26). NOD/LtJ wild-
type CD3 T-cells transmigrated across islet microvascular
endothelium toward the chemoattractant RANTES (100
ng/ml) at a much higher rate than toward HBSS control
treatment (Fig. 4C). When islet endothelial cells were
activated with TNF-, with or without RANTES chemoat-
tractant, T-cell transmigration was also increased, but to a
lesser degree. The same effect was seen when CD3
T-cells from ItgaL
/ NOD/LtJ mice were used, with a
greater increase in transmigration of T-cells in response
to RANTES (Fig. 4D). These data demonstrate that
genetic deﬁciency of ItgaL does not inhibit the ability of
NOD/LtJ T-cells to transmigrate across pancreatic islet
endothelial cell monolayers.
ItgaL deﬁciency increases NOD/LtJ T-cell CD11b
expression and function. Flow cytometry analysis of
ItgaL null T-cells revealed the unexpected ﬁnding of
residual CD18 (Itgb2) expression on the surface coupled
with the observation that ItgaL null T-cells are still capable
of ﬁrm adhesion and transmigration. Therefore, experi-
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FIG. 4. Genetic deﬁciency of Itgb2 but not ItgaL blunts NOD/LtJ T-cell ﬁrm adhesion under hydrodynamic ﬂow conditions. CD3 T-cells were
isolated from either diabetic wild-type, Itgb2
/ null, or ItgaL
/ null NOD/LtJ mice and perfused over either unstimulated or TNF-–stimulated
(10 ng/ml) islet microvascular endothelial cells at physiological shear stress. A: The average rolling velocity of the different T-cells on
unstimulated or TNF-–stimulated islet endothelial cells. B: The percent increase in T-cell ﬁrm adhesion to either unstimulated or TNF-–
stimulated islet endothelial cells. CD3 T-cells from diabetic wild-type and ItgaL null mice were evaluated for their ability to transmigrate across
either unstimulated or TNF-–stimulated islet endothelial cells toward a chemotactic gradient of RANTES (100 ng/ml). C: Wild-type diabetic
NOD/LtJ T-cell transmigration. D: ItgaL
/ null NOD/LtJ T-cell transmigration. *P < 0.01, n  8.
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of these residual integrins. Figure 5A shows that a signif-
icantly greater percent of ItgaL null CD3 T-cells are
positive for CD11b expression, whereas there was no
difference in CD11c positivity among the different strains
of mice (Fig. 5B). Consistent with this ﬁnding, Fig. 5C
illustrates that the mean ﬂuorescence intensity of CD11b
expression was signiﬁcantly enhanced on ItgaL null T-cells
compared with CD11c (Fig. 5D). Interestingly, blockade
of CD11b function with a neutralizing antibody com-
pletely prevented ItgaL null T-cell adhesion to TNF-–
activated islet microvascular endothelial cell
monolayers under ﬂow conditions (Fig. 5E). Conversely,
anti-CD11b antibody treatment did not alter diabetic
wild-type T-cell adhesion to TNF-–activated islet endo-
thelium (Fig. 5F). These data indicate that genetic
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stained for CD3 and either CD11b or CD11c to determine what other 2 integrins could be expressed in ItgaL null cells. A and B: The percent of
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functional CD11b on NOD/LtJ T-cells.
Adoptive transfer of ItgaL splenocytes does not elicit
autoimmune diabetes. Data from ItgaL
/ NOD/LtJ mice
suggest that the primary reason for protection against the
development of autoimmune diabetes is likely attributable
to defects in immune cell activation rather than deﬁcien-
cies in T-cell recruitment across islet microvascular endo-
thelial cells. Moreover, ItgaL is also expressed on antigen-
presenting cells and is involved in immune synapse
formation (27), leaving the possibility that protection in
the ItgaL mice could involve other immune cell responses
independent of T-cell recruitment. Therefore, we per-
formed adoptive transfer experiments using ItgaL
/
splenocytes into NOD/LtJ Rag-1
/ mice to directly ad-
dress whether T-cell behavior is altered. NOD/LtJ Rag-1
/
mice injected with 2  10
7 splenocytes from diabetic
NOD/LtJ mice developed hyperglycemia in 5–7 weeks,
whereas those receiving cells from ItgaL-deﬁcient NOD/
LtJ mice were normoglycemic and did not develop diabe-
tes, as shown in Fig. 6A and B. Insulitis scores conﬁrm that
splenocytes from diabetic NOD/LtJ mice transferred into
NOD Rag-1
/ mice promoted insulitis quickly, resulting
in islets that were completely obliterated (insulitis score of
4) in 2 weeks after onset of hyperglycemia. However, no
insulitis was observed in any ItgaL
/ transfer experi-
ments (data not shown). A greater number of leukocytes
and CD3
 T-cells were found in NOD Rag-1
/ mice
spleens injected with cells from ItgaL
/ NOD/LtJ mice
than from diabetic wild-type NOD/LtJ mice (Fig. 6C),
indicating that T-cells from ItgaL
/ mice are retained in
the spleen. Lastly, Fig. 6D shows that ItgaL deﬁciency does
not alter the percent distribution of leukocytes that were
CD3
 or the ratio of CD4
 to CD8
 T-cells, conﬁrming that
loss of ItgaL does not differentially alter different lympho-
cyte populations.
DISCUSSION
Regulation of leukocyte recruitment into speciﬁc tissue
niches is a critical innate immune response event. How-
ever, it has become increasing more apparent that immune
cell recruitment is important for acquired immune re-
sponses involved in autoimmunity (12,13,28–33). Several
different adhesion molecules facilitate the process of
leukocyte recruitment, and many of these have been
implicated in the development of autoimmune diabetes
(9,34,35). However, identiﬁcation of key proteins and their
mechanisms of action still remain elusive. In this study, we
determined the importance of leukocyte integrins Itgb2
and ItgaL for the development of autoimmune diabetes
using gene-targeted null mutations of either gene.
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subunits were protected from diabetes, as evidenced by
both blood glucose measurements and histopathology.
These ﬁndings were striking for two reasons. First, mem-
bers of the 1 integrin family have long been suspected to
play an important role in modulating autoimmune cell
inﬁltration into tissues (36–39). That genetic deﬁciencies
of either Itgb2 or ItgaL in NOD/LtJ mice prevented disease
suggests that Itgb2 play a dominant role in autoimmune
diabetes pathogenesis because expression of Itgb1 was
still observed and actually enhanced in Itgb2 null NOD/LtJ
mice, yet these mice were protected against autoimmune
diabetes. Second, these results suggest that Itgb2 het-
erodimeric association with ItgaL is likely the pathophys-
iological heterodimer of the Itgb2 family necessary for
autoimmune diabetes. This is due to the fact that genetic
deﬁciency of Itgb2 results in loss of all four Itgb2 integrin
proteins (ItgaL, ItgaM, ItgaX, and ItgaD) from the cell
surface because intracellular chain pairing is necessary for
surface localization and that other Itgb2 heterodimers
(ItgaM/Itgb2) are enhanced in the ItgaL null mutation (13).
Together, these data demonstrate that functional disrup-
tion of these molecules is a highly effective means by
which to halt the development of autoimmune diabetes.
Another important result of this study was the manner
in which gene-deﬁcient mutations of either Itgb2 or ItgaL
conferred protection against the development of diabetes.
Genetic deﬁciency of Itgb2 inhibited autoimmune diabetes
because of defective T-cell recruitment and adhesion to
islet microvascular endothelial cells. However, deﬁciency
of ItgaL likely limits T-cell activation with lesser effects on
T-cell adhesion or transmigration apparently because of
increased surface localization of CD11b. This ﬁnding could
be caused by increased CD11b gene expression; however,
additional studies are needed to better understand this
surprising observation. Moreover, these results are an
excellent example of differential integrin functions during
disease. Previous studies investigating the role of adhesion
molecules (e.g., lymphocyte function–associated antigen-
1/intercellular adhesion molecule-1) have all used immu-
noblockade approaches with combined antibody therapies
(40–43). Although this approach may be useful, it has not
provided a clear understanding of how and to what extent
each integrin chain contributes to disease pathogenesis.
Moreover, immunoneutralization approaches against ad-
hesion molecules have been reported to involve off-target
effects and responses (44,45). Thus, our work using gene-
targeted deﬁciency of speciﬁc leukocyte integrin chains
provides a precise understanding of the importance of
these molecules during disease and the molecular mecha-
nisms by which they act.
Adoptive transfer experiments using ItgaL null spleno-
cytes into Rag-1–deﬁcient NOD/LtJ mice suggest that this
integrin may also be involved in immune cell homing to
lymphoid tissue necessary for antigen-dependent activa-
tion. It has been reported that ItgaL-deﬁcient T-cells
exhibit defective homing to peripheral and mucosal tissue
lymph nodes, whereas homing to the spleen is less altered
(46). Our data are suggestive of a defective homing re-
sponse with ItgaL null splenocytes, as seen by a threefold
increase in total leukocytes and a twofold increase in CD3
T-cells in spleens of adoptive transfer Rag-1 null NOD/LtJ
mice. Importantly, deﬁciency of ItgaL does not alter the
distribution of different T-cell populations (CD4 vs. CD8)
during adoptive transfer, reinforcing the notion that loss of
this molecule does not adversely affect cell proliferation
and survival in this model. This ﬁnding coupled with the
fact that ItgaL deﬁciency still results in some (albeit
minimal) insulitis along with intact adhesion responses
strongly suggests that diminished T-cell activation plays a
large role in the protection against autoimmune diabetes.
However, future experiments are necessary to precisely
determine how loss of ItgaL speciﬁcally alters NOD/LtJ
T-cell activation and homing.
In summary, our work demonstrates that Itgb2 or ItgaL
serve as dominant adhesion molecule regulators of auto-
immunity, highlighting the importance of innate immune
responses, which clearly inﬂuence disease progression.
Moreover, these results suggest that therapeutic interven-
tion aimed at these molecules could be clinically useful for
autoimmune diabetes. Indeed, eﬂaizumab (anti-ItgaL anti-
body) is a well-established and -tolerated therapy for
autoimmune psoriasis that is currently in clinical trials for
islet transplantation in type 1 diabetic patients; however,
eﬂaizumab therapy could also be useful in patients at high
risk of type 1 diabetes or those recently diagnosed with
type 1 diabetes.
ACKNOWLEDGMENTS
This work was supported by American Diabetes Associa-
tion Grant 05-JF-26 (to C.G.K.).
No potential conﬂicts of interest relevant to this article
were reported.
REFERENCES
1. Sia C, Weinem M. The role of HLA class I gene variation in autoimmune
diabetes. Rev Diabet Stud 2005;2:97–109
2. Sia C. Imbalance in Th cell polarization and its relevance in type 1 diabetes
mellitus. Rev Diabet Stud 2005;2:182–186
3. Tritt M, Sgouroudis E, d’Hennezel E, Albanese A, Piccirillo CA. Functional
waning of naturally occurring CD4 regulatory T-cells contributes to the
onset of autoimmune diabetes. Diabetes 2008;57:113–123
4. Sia C, Weinem M. Genetic susceptibility to type 1 diabetes in the
intracellular pathway of antigen processing: a subject review and cross-
study comparison. Rev Diabet Stud 2005;2:40–52
5. Bradley LM, Asensio VC, Schioetz LK, Harbertson J, Krahl T, Patstone G,
Woolf N, Campbell IL, Sarvetnick N. Islet-speciﬁc Th1, but not Th2, cells
secrete multiple chemokines and promote rapid induction of autoimmune
diabetes. J Immunol 1999;162:2511–2520
6. Blann AD, Lip GY. Endothelial integrity, soluble adhesion molecules and
platelet markers in type 1 diabetes mellitus. Diabet Med 1998;15:634–642
7. Martin S. Soluble adhesion molecules in type 1 diabetes mellitus. Horm
Metab Res 1997;29:639–642
8. Michie SA, Sytwu HK, McDevitt JO, Yang XD. The roles of alpha 4-integrins
in the development of insulin-dependent diabetes mellitus. Curr Top
Microbiol Immunol 1998;231:65–83
9. Yang XD, Michie SA, Mebius RE, Tisch R, Weissman I, McDevitt HO. The
role of cell adhesion molecules in the development of IDDM: implications
for pathogenesis and therapy. Diabetes 1996;45:705–710
10. Harris ES, McIntyre TM, Prescott SM, Zimmerman GA. The leukocyte
integrins. J Biol Chem 2000;275:23409–23412
11. Bunting M, Harris ES, McIntyre TM, Prescott SM, Zimmerman GA.
Leukocyte adhesion deﬁciency syndromes: adhesion and tethering defects
involving beta 2 integrins and selectin ligands. Curr Opin Hematol 2002;9:
30–35
12. Barlow SC, Langston W, Matthews KM, Chidlow JH Jr, Kevil CG. CD18
deﬁciency protects against multiple low-dose streptozotocin-induced dia-
betes. Am J Pathol 2004;165:1849–1852
13. Kevil CG, Hicks MJ, He X, Zhang J, Ballantyne CM, Raman C, Schoeb TR,
Bullard DC. Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice
from autoimmune disease. Am J Pathol 2004;165:609–616
14. Scharffetter-Kochanek K, Lu H, Norman K, van Nood N, Munoz F, Grabbe
S, McArthur M, Lorenzo I, Kaplan S, Ley K, Smith C, Montgomery C, Rich
S, Beaudet A. Spontaneous skin ulceration and defective T cell function in
CD18 null mice. J Exp Med 1998;188:119–131
15. Walzog B, Weinmann P, Jeblonski F, Scharffetter-Kochanek K, Bommert K,
Gaehtgens P. A role for beta(2) integrins (CD11/CD18) in the regulation of
Itgb2 OR ItgaL DEFICIENCY PREVENTS DIABETES
1300 DIABETES, VOL. 58, JUNE 2009cytokine gene expression of polymorphonuclear neutrophils during the
inﬂammatory response. FASEB J 1999;13:1855–1865
16. Mysliwiec J, Kretowski A, Kinalski M, Kinalska I. CD11a expression and
soluble ICAM-1 levels in peripheral blood in high-risk and overt type 1
diabetes subjects. Immunol Lett 1999;70:69–72
17. Martin S, Hibino T, Faust A, Kleemann R, Kolb H. Differential expression
of ICAM-1 and LFA-1 versus L-selectin and VCAM-1 in autoimmune
insulitis of NOD mice and association with both Th1- and Th2-type
inﬁltrates. J Autoimmun 1996;9:637–643
18. Kretowski A, Mysliwiec J, Kinalska I. The alterations of CD11A expression
on peripheral blood lymphocytes/monocytes and CD62L expression on
peripheral blood lymphocytes in Graves’ disease and type 1 diabetes. Rocz
Akad Med Bialymst 1999;44:151–159
19. Hanninen A, Salmi M, Simell O, Jalkanen S. Endothelial cell-binding
properties of lymphocytes inﬁltrated into human diabetic pancreas: impli-
cations for pathogenesis of IDDM. Diabetes 1993;42:1656–1662
20. Sharp CD, Huang M, Glawe J, Patrick DR, Pardue S, Barlow SC, Kevil CG.
Stromal cell-derived factor-1/CXCL12 stimulates chemorepulsion of NOD/
LtJ T-cell adhesion to islet microvascular endothelium. Diabetes 2008;57:
102–112
21. Huang M, Matthews K, Siahaan TJ, Kevil CG. Alpha L-integrin I domain
cyclic peptide antagonist selectively inhibits T cell adhesion to pancreatic
islet microvascular endothelium. Am J Physiol Gastrointest Liver Physiol
2005;288:G67–G73
22. Savinov AY, Rozanov DV, Strongin AY. Mechanistic insights into targeting
T cell membrane proteinase to promote islet beta-cell rejuvenation in type
1 diabetes. FASEB J 2006;20:1793–1801
23. Kandula S, Abraham C. LFA-1 on CD4 T cells is required for optimal
antigen-dependent activation in vivo. J Immunol 2004;173:4443–4451
24. Marski M, Kandula S, Turner JR, Abraham C. CD18 is required for optimal
development and function of CD4CD25 T regulatory cells. J Immunol
2005;175:7889–7897
25. Wu H, Rodgers JR, Perrard XY, Perrard JL, Prince JE, Abe Y, Davis BK,
Dietsch G, Smith CW, Ballantyne CM. Deﬁciency of CD11b or CD11d
results in reduced staphylococcal enterotoxin-induced T cell response and
T cell phenotypic changes. J Immunol 2004;173:297–306
26. Hogg N, Laschinger M, Giles K, McDowall A. T-cell integrins: more than
just sticking points. J Cell Sci 2003;116:4695–4705
27. Sims TN, Dustin ML. The immunological synapse: integrins take the stage.
Immunol Rev 2002;186:100–117
28. Bullard DC, King PD, Hicks MJ, Dupont B, Beaudet AL, Elkon KB.
Intercellular adhesion molecule-1 deﬁciency protects MRL/MpJ-Faslpr
mice from early lethality. J Immunol 1997;159:2058–2067
29. Carter RA, Wicks IP. Vascular cell adhesion molecule 1 (CD106): a
multifaceted regulator of joint inﬂammation. Arthritis Rheum 2001;44:985–
994
30. Kevil C, Bullard D. Roles of leukocyte/endothelial cell adhesion molecules
in the pathogenesis of vasculitis. Am J Med 1999;106:677–687
31. Kevil CG, Bullard DC. Cell adhesion molecules in the rheumatic diseases.
In Arthritis and Allied Conditions. Koopman W, Ed. Philadelphia, PA,
Lippincott Williams & Wilkins, 2001, p. 478–489
32. McMurray RW. Adhesion molecules in autoimmune disease. Semin Arthri-
tis Rheum 1996;25:215–233
33. Rodriguez-Fernandez JL, Corbi AL. Adhesion molecules in human den-
dritic cells. Curr Opin Investig Drugs 2005;6:1103–1111
34. Faveeuw C, Gagnerault MC, Lepault F. Expression of homing and adhesion
molecules in inﬁltrated islets of Langerhans and salivary glands of nono-
bese diabetic mice. J Immunol 1994;152:5969–5978
35. Fabien N, Bergerot I, Orgiazzi J, Thivolet C. Lymphocyte function associ-
ated antigen-1, integrin alpha 4, and L-selectin mediate T-cell homing to the
pancreas in the model of adoptive transfer of diabetes in NOD mice.
Diabetes 1996;45:1181–1186
36. Baron JL, Reich EP, Visintin I, Janeway CA Jr. The pathogenesis of
adoptive murine autoimmune diabetes requires an interaction between
alpha 4-integrins and vascular cell adhesion molecule-1. J Clin Invest
1994;93:1700–1708
37. Hanninen A, Nurmela R, Maksimow M, Heino J, Jalkanen S, Kurts C. Islet
beta-cell-speciﬁc T cells can use different homing mechanisms to inﬁltrate
and destroy pancreatic islets. Am J Pathol 2007;170:240–250
38. McMurray RW, Tang H, Braley-Mullen H. The role of alpha 4 integrin and
intercellular adhesion molecule-1 (ICAM-1) in murine experimental auto-
immune thyroiditis. Autoimmunity 1996;23:9–23
39. Tsukamoto K, Yokono K, Amano K, Nagata M, Yagi N, Tominaga Y,
Moriyama H, Miki M, Okamoto N, Yoneda R, et al. Administration of
monoclonal antibodies against vascular cell adhesion molecule-1/very late
antigen-4 abrogates predisposing autoimmune diabetes in NOD mice. Cell
Immunol 1995;165:193–201
40. Bertry-Coussot L, Lucas B, Danel C, Halbwachs-Mecarelli L, Bach JF,
Chatenoud L, Lemarchand P. Long-term reversal of established autoimmu-
nity upon transient blockade of the LFA-1/intercellular adhesion mole-
cule-1 pathway. J Immunol 2002;168:3641–3648
41. Chowdhury SA, Nagata M, Yamada K, Nakayama M, Chakrabarty S, Jin Z,
Kotani R, Yokono K. Tolerance mechanisms in murine autoimmune
diabetes induced by anti-ICAM-1/LFA-1 mab and anti-CD8 mab. Kobe
J Med Sci 2002;48:167–175
42. Hayashi T, Hashimoto S, Kameyama Y. Reduced streptozotocin-induced
insulitis in CD-1 mice by treatment with anti-intercellular adhesion mole-
cule-1 and anti-lymphocyte function associated antigen-1 monoclonal
antibodies together with lactic dehydrogenase virus infection. Int J Exp
Pathol 1994;75:117–121
43. Moriyama H, Yokono K, Amano K, Nagata M, Hasegawa Y, Okamoto N,
Tsukamoto K, Miki M, Yoneda R, Yagi N, Tominaga Y, Kikutani H, Hioki K,
Okumura K, Yagita H, Kasuga M. Induction of tolerance in murine
autoimmune diabetes by transient blockade of leukocyte function-associ-
ated antigen-1/intercellular adhesion molecule-1 pathway. J Immunol
1996;157:3737–3743
44. Driessens MH, van Hulten P, Zuurbier A, La Riviere G, Roos E. Inhibition
and stimulation of LFA-1 and Mac-1 functions by antibodies against murine
CD18: evidence that the LFA-1 binding sites for ICAM-1, -2, and -3 are
distinct. J Leukoc Biol 1996;60:758–765
45. Gadd SJ, Eher R, Majdic O, Knapp W. Signal transduction via Fc gamma R
and Mac-1 alpha-chain in monocytes and polymorphonuclear leucocytes.
Immunology 1994;81:611–617
46. Berlin-Rufenach C, Otto F, Mathies M, Westermann J, Owen MJ, Hamann
A, Hogg N. Lymphocyte migration in lymphocyte function-associated
antigen (LFA)-1-deﬁcient mice. J Exp Med 1999;189:1467–1478
J.D. GLAWE AND ASSOCIATES
DIABETES, VOL. 58, JUNE 2009 1301